12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cadazolid: Phase II data

A double-blind Phase II trial in 84 patients with CDAD showed that twice-daily 250, 500 and 1,000 mg oral cadazolid for 10 days each produced "numerically similar" clinical cure rates, the primary endpoint defined as the resolution of diarrhea and no further need for CDAD therapy at the...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >